Subscribe to RSS
DOI: 10.1055/s-0039-1700512
Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment

Abstract
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting approximately 1 in 20,000 people. Patients typically present with clinically benign mucocutaneous bleeding, but morbid internal bleeding can occur. Diagnosis remains clinical, possible only after ruling out other causes of thrombocytopenia through history and laboratory testing. Many adult patients do not require treatment. For those requiring intervention, initial treatment of adult ITP is with corticosteroids, intravenous immunoglobulin, or intravenous anti-RhD immune globulin. These agents are rapid-acting but do not result in durable remissions in most patients. No corticosteroid has demonstrated superiority to others for ITP treatment. Subsequent treatment of adult ITP is typically with thrombopoietin receptor agonists (TPO-RAs; romiplostim or eltrombopag), rituximab, or splenectomy. TPO-RAs are newer agents that offer an excellent response rate but may require prolonged treatment. The choice between subsequent treatments involves consideration of operative risk, risk of asplenia, drug side-effects, quality-of-life issues, and financial costs. Given the efficacy of medical therapies and the rate of spontaneous remission in the first year after diagnosis, splenectomy is frequently deferred in modern ITP treatment algorithms. Fostamatinib (a tyrosine kinase inhibitor recently approved by the U.S. Food and Drug Administration) and several older immunosuppressive agents (azathioprine, cyclophosphamide, cyclosporine, danazol, dapsone, mycophenolate mofetil, and the Vinca alkaloids) may be useful in patients with disease unresponsive to standard therapies or in specific clinical circumstances. This comprehensive review explores diagnostic considerations and surveys new and old treatment options for adults with ITP.
Keywords
platelets - immune thrombocytopenia - diagnosis - treatment - corticosteroids - intravenous immunoglobulin - splenectomy - thrombopoietin receptor agonist - rituximab - fostamatinibAuthors' Contributions
H.A. drafted the manuscript, created the tables and figures, and contributed to the concept and design, critical revision of the intellectual content, and final approval. D.J.K. contributed to the concept and design, critical revision of the intellectual content, and final approval.
Publication History
Publication Date:
12 December 2019 (online)
© 2020. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1
Harrington WJ,
Minnich V,
Hollingsworth JW,
Moore CV.
Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic
purpura. J Lab Clin Med 1951; 38 (01) 1-10
MissingFormLabel
- 2
Harker LA,
Finch CA.
Thrombokinetics in man. J Clin Invest 1969; 48 (06) 963-974
MissingFormLabel
- 3
McMillan R,
Wang L,
Tomer A,
Nichol J,
Pistillo J.
Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from
adult patients with chronic ITP. Blood 2004; 103 (04) 1364-1369
MissingFormLabel
- 4
Neunert C,
Lim W,
Crowther M,
Cohen A,
Solberg Jr L,
Crowther MA.
American Society of Hematology.
The American Society of Hematology 2011 evidence-based practice guideline for immune
thrombocytopenia. Blood 2011; 117 (16) 4190-4207
MissingFormLabel
- 5
Provan D,
Stasi R,
Newland AC.
et al.
International consensus report on the investigation and management of primary immune
thrombocytopenia. Blood 2010; 115 (02) 168-186
MissingFormLabel
- 6
Frederiksen H,
Schmidt K.
The incidence of idiopathic thrombocytopenic purpura in adults increases with age.
Blood 1999; 94 (03) 909-913
MissingFormLabel
- 7
Neylon AJ,
Saunders PW,
Howard MR,
Proctor SJ,
Taylor PR.
Northern Region Haematology Group.
Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults:
a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;
122 (06) 966-974
MissingFormLabel
- 8
Butros LJ,
Bussel JB.
Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis.
J Pediatr Hematol Oncol 2003; 25 (08) 660-664
MissingFormLabel
- 9
Cohen YC,
Djulbegovic B,
Shamai-Lubovitz O,
Mozes B.
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients
with persistent low platelet counts. Arch Intern Med 2000; 160 (11) 1630-1638
MissingFormLabel
- 10
Newton JL,
Reese JA,
Watson SI.
et al.
Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol 2011;
86 (05) 420-429
MissingFormLabel
- 11
Hill QA,
Newland AC.
Fatigue in immune thrombocytopenia. Br J Haematol 2015; 170 (02) 141-149
MissingFormLabel
- 12
Vrbensky JR,
Moore JE,
Arnold DM,
Smith JW,
Kelton JG,
Nazy I.
The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia:
a systematic review and meta-analysis of a diagnostic test. J Thromb Haemost 2019;
17 (05) 787-794
MissingFormLabel
- 13
Al-Samkari H,
Kuter DJ.
Antiplatelet antibody testing in immune thrombocytopenia and Evans syndrome: longitudinal
serologic evolution and relation to clinical features [abstract]. Blood 2018; 132
(Suppl. 01) 1137
MissingFormLabel
- 14
Al-Samkari H,
Kuter DJ.
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim
in immune thrombocytopenia. Am J Hematol 2018; 93 (12) 1501-1508
MissingFormLabel
- 15
Rodeghiero F,
Stasi R,
Gernsheimer T.
et al.
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic
purpura of adults and children: report from an international working group. Blood
2009; 113 (11) 2386-2393
MissingFormLabel
- 16
Portielje JE,
Westendorp RG,
Kluin-Nelemans HC,
Brand A.
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood
2001; 97 (09) 2549-2554
MissingFormLabel
- 17
Sailer T,
Lechner K,
Panzer S,
Kyrle PA,
Pabinger I.
The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy.
Haematologica 2006; 91 (08) 1041-1045
MissingFormLabel
- 18
Slichter SJ,
Harker LA.
Thrombocytopenia: mechanisms and management of defects in platelet production. Clin
Haematol 1978; 7 (03) 523-539
MissingFormLabel
- 19
Slichter SJ,
Kaufman RM,
Assmann SF.
et al.
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J
Med 2010; 362 (07) 600-613
MissingFormLabel
- 20
Lacey JV,
Penner JA.
Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost
1977; 3 (03) 160-174
MissingFormLabel
- 21
Chantarangkul V,
Clerici M,
Bressi C,
Tripodi A.
Standardization of the endogenous thrombin potential measurement: how to minimize
the effect of residual platelets in stored plasma. Br J Haematol 2004; 124 (03) 355-357
MissingFormLabel
- 22
Harker LA,
Slichter SJ.
The bleeding time as a screening test for evaluation of platelet function. N Engl
J Med 1972; 287 (04) 155-159
MissingFormLabel
- 23
Nagrebetsky A,
Al-Samkari H,
Davis NM,
Kuter DJ,
Wiener-Kronish JP.
Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. Br J
Anaesth 2019; 122 (01) 19-31
MissingFormLabel
- 24
Shulman NR,
Weinrach RS,
Libre EP,
Andrews HL.
The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic
purpura. Trans Assoc Am Physicians 1965; 78: 374-390
MissingFormLabel
- 25
Gernsheimer T,
Stratton J,
Ballem PJ,
Slichter SJ.
Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl
J Med 1989; 320 (15) 974-980
MissingFormLabel
- 26
Kitchens CS.
Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia
in the rabbit. J Clin Invest 1977; 60 (05) 1129-1134
MissingFormLabel
- 27
Kitchens CS,
Weiss L.
Ultrastructural changes of endothelium associated with thrombocytopenia. Blood 1975;
46 (04) 567-578
MissingFormLabel
- 28
Nakazaki K,
Hosoi M,
Hangaishi A,
Ichikawa M,
Nannya Y,
Kurokawa M.
Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy
for adult primary immune thrombocytopenia: a retrospective study. Intern Med 2012;
51 (08) 859-863
MissingFormLabel
- 29
Bae SH,
Ryoo HM,
Lee WS.
et al.
High dose dexamethasone vs. conventional dose prednisolone for adults with immune
thrombocytopenia: a prospective multicenter phase III trial [abstract]. Blood 2010;
116 (21) 3687
MissingFormLabel
- 30
Wei Y,
Ji XB,
Wang YW.
et al.
High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia:
a prospective multicenter randomized trial. Blood 2016; 127 (03) 296-302 , quiz 370
MissingFormLabel
- 31
Mithoowani S,
Gregory-Miller K,
Goy J.
et al.
High-dose dexamethasone compared with prednisone for previously untreated primary
immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2016;
3 (10) e489-e496
MissingFormLabel
- 32
Gómez-Almaguer D,
Tarín-Arzaga L,
Moreno-Jaime B.
et al.
High response rate to low-dose rituximab plus high-dose dexamethasone as frontline
therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol 2013;
90 (06) 494-500
MissingFormLabel
- 33
Gudbrandsdottir S,
Birgens HS,
Frederiksen H.
et al.
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients
with primary immune thrombocytopenia. Blood 2013; 121 (11) 1976-1981
MissingFormLabel
- 34
Zaja F,
Baccarani M,
Mazza P.
et al.
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone
monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115 (14) 2755-2762
MissingFormLabel
- 35
Chapin J,
Lee CS,
Zhang H,
Zehnder JL,
Bussel JB.
Gender and duration of disease differentiate responses to rituximab-dexamethasone
therapy in adults with immune thrombocytopenia. Am J Hematol 2016; 91 (09) 907-911
MissingFormLabel
- 36
Bussel JB,
Lee CS,
Seery C.
et al.
Rituximab and three dexamethasone cycles provide responses similar to splenectomy
in women and those with immune thrombocytopenia of less than two years duration. Haematologica
2014; 99 (07) 1264-1271
MissingFormLabel
- 37
Chugh S,
Darvish-Kazem S,
Lim W.
et al.
Rituximab plus standard of care for treatment of primary immune thrombocytopenia:
a systematic review and meta-analysis. Lancet Haematol 2015; 2 (02) e75-e81
MissingFormLabel
- 38
Zhang L,
Zhang M,
Du X,
Cheng Y,
Cheng G.
Eltrombopag plus pulsed dexamethasone as first line therapy for subjects with immune
thrombocytopenic purpura (ITP) [abstract]. Blood 2018; 132 (Suppl. 01) 733
MissingFormLabel
- 39
Nimmerjahn F,
Ravetch JV.
Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26:
513-533
MissingFormLabel
- 40
Deng R,
Balthasar JP.
Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune
thrombocytopenia. J Pharm Sci 2007; 96 (06) 1625-1637
MissingFormLabel
- 41
Newman GC,
Novoa MV,
Fodero EM,
Lesser ML,
Woloski BM,
Bussel JB.
A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly
and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic
purpura. Br J Haematol 2001; 112 (04) 1076-1078
MissingFormLabel
- 42
Tarantino MD,
Young G,
Bertolone SJ.
et al;
Acute ITP Study Group.
Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous
immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic
purpura in children. J Pediatr 2006; 148 (04) 489-494
MissingFormLabel
- 43
Kumagai Y,
Fujita T,
Ozaki M.
et al.
Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody,
in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol
2007; 47 (12) 1489-1497
MissingFormLabel
- 44
Jenkins JM,
Williams D,
Deng Y.
et al.
Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor
agonist. Blood 2007; 109 (11) 4739-4741
MissingFormLabel
- 45
Nomoto M,
Pastino G,
Rege B,
Aluri J,
Ferry J,
Han D.
Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of
avatrombopag in healthy Japanese and white subjects. Clin Pharmacol Drug Dev 2018;
7 (02) 188-195
MissingFormLabel
- 46
Carr JM,
Kruskall MS,
Kaye JA,
Robinson SH.
Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986; 80 (06)
1051-1054
MissingFormLabel
- 47
Spahr JE,
Rodgers GM.
Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous
immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am
J Hematol 2008; 83 (02) 122-125
MissingFormLabel
- 48
American College of Obstetricians and Gynecologists.
ACOG Practice Bulletin: Thrombocytopenia in pregnancy. Number 6, September 1999. Clinical
management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet 1999;
67 (02) 117-128
MissingFormLabel
- 49
Webert KE,
Mittal R,
Sigouin C,
Heddle NM,
Kelton JG.
A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic
purpura. Blood 2003; 102 (13) 4306-4311
MissingFormLabel
- 50
Al-Jama FE,
Rahman J,
Al-Suleiman SA,
Rahman MS.
Outcome of pregnancy in women with idiopathic thrombocytopenic purpura. Aust N Z J
Obstet Gynaecol 1998; 38 (04) 410-413
MissingFormLabel
- 51
Wyszynski DF,
Carman WJ,
Cantor AB.
et al.
Pregnancy and birth outcomes among women with idiopathic thrombocytopenic purpura.
J Pregnancy 2016; 2016: 8297407
MissingFormLabel
- 52
Nicolescu A,
Vladareanu AM,
Voican I,
Onisai M,
Vladareanu R.
Therapeutic options for immune thrombocytopenia (ITP) during pregnancy. Maedica (Buchar)
2013; 8 (02) 182-188
MissingFormLabel
- 53
Gernsheimer T,
James AH,
Stasi R.
How I treat thrombocytopenia in pregnancy. Blood 2013; 121 (01) 38-47
MissingFormLabel
- 54
Neunert CE,
Cooper N.
Evidence-based management of immune thrombocytopenia: ASH guideline update. Hematology
(Am Soc Hematol Educ Program) 2018; 2018 (01) 568-575
MissingFormLabel
- 55
Schwartz J,
Leber MD,
Gillis S,
Giunta A,
Eldor A,
Bussel JB.
Long term follow-up after splenectomy performed for immune thrombocytopenic purpura
(ITP). Am J Hematol 2003; 72 (02) 94-98
MissingFormLabel
- 56
Boyle S,
White RH,
Brunson A,
Wun T.
Splenectomy and the incidence of venous thromboembolism and sepsis in patients with
immune thrombocytopenia. Blood 2013; 121 (23) 4782-4790
MissingFormLabel
- 57
Morbieu C,
Brunetti F,
Baranès L.
et al.
Systematic detection of portal or splenic vein thrombosis after splenectomy for immune
cytopenia. Am J Hematol 2018; 93 (07) E170-E172
MissingFormLabel
- 58
Swirski FK,
Nahrendorf M,
Etzrodt M.
et al.
Identification of splenic reservoir monocytes and their deployment to inflammatory
sites. Science 2009; 325 (5940): 612-616
MissingFormLabel
- 59
Sun LM,
Chen HJ,
Jeng LB,
Li TC,
Wu SC,
Kao CH.
Splenectomy and increased subsequent cancer risk: a nationwide population-based cohort
study. Am J Surg 2015; 210 (02) 243-251
MissingFormLabel
- 60
Newland A,
Godeau B,
Priego V.
et al.
Remission and platelet responses with romiplostim in primary immune thrombocytopenia:
final results from a phase 2 study. Br J Haematol 2016; 172 (02) 262-273
MissingFormLabel
- 61
Marshall AL,
Scarpone R,
De Greef M,
Bird R,
Kuter DJ.
Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica
2016; 101 (12) e476-e478
MissingFormLabel
- 62
Desmond R,
Townsley DM,
Dumitriu B.
et al.
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia
that can be sustained on discontinuation of drug. Blood 2014; 123 (12) 1818-1825
MissingFormLabel
- 63
Afdhal NH,
Dusheiko GM,
Giannini EG.
et al.
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection
and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014; 146
(02) 442-52.e1
MissingFormLabel
- 64
Al-Samkari H,
Marshall AL,
Goodarzi K,
Kuter DJ.
The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients
with solid tumors. Haematologica 2018; 103 (04) e169-e172
MissingFormLabel
- 65
Al-Samkari H,
Marshall AL,
Goodarzi K,
Kuter DJ.
Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol 2018;
182 (01) 106-113
MissingFormLabel
- 66
Kantarjian H,
Fenaux P,
Sekeres MA.
et al.
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome
and thrombocytopenia. J Clin Oncol 2010; 28 (03) 437-444
MissingFormLabel
- 67
Cheng G,
Saleh MN,
Marcher C.
et al.
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month,
randomised, phase 3 study. Lancet 2011; 377 (9763): 393-402
MissingFormLabel
- 68
Kuter DJ,
Bussel JB,
Lyons RM.
et al.
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:
a double-blind randomised controlled trial. Lancet 2008; 371 (9610): 395-403
MissingFormLabel
- 69
Bussel JB,
Provan D,
Shamsi T.
et al.
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic
idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled
trial. Lancet 2009; 373 (9664): 641-648
MissingFormLabel
- 70
González-López TJ,
Pascual C,
Álvarez-Román MT.
et al.
Successful discontinuation of eltrombopag after complete remission in patients with
primary immune thrombocytopenia. Am J Hematol 2015; 90 (03) E40-E43
MissingFormLabel
- 71
Makar RS,
Zhukov OS,
Sahud MA,
Kuter DJ.
Thrombopoietin levels in patients with disorders of platelet production: diagnostic
potential and utility in predicting response to TPO receptor agonists. Am J Hematol
2013; 88 (12) 1041-1044
MissingFormLabel
- 72
Kuter DJ,
Meibohm A,
Lopez A.
TPO concentrations and response to romiplostim. Am J Hematol 2014; 89 (12) 1155-1156
MissingFormLabel
- 73
Nomoto M,
Ferry J,
Hussein Z.
Population pharmacokinetic/pharmacodynamic analyses of avatrombopag in patients with
chronic liver disease and optimal dose adjustment guide with concomitantly administered
CYP3A and CYP2C9 inhibitors. J Clin Pharmacol 2018; 58 (12) 1629-1638
MissingFormLabel
- 74
Williams DD,
Peng B,
Bailey CK.
et al.
Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult
subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin
Ther 2009; 31 (04) 764-776
MissingFormLabel
- 75
Wire MB,
Bruce J,
Gauvin J.
et al.
A randomized, open-label, 5-period, balanced crossover study to evaluate the relative
bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations
and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered
with or 2 hours before or after PfOS. Clin Ther 2012; 34 (03) 699-709
MissingFormLabel
- 76
Al-Samkari H.
Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients
with chronic liver disease. Drugs Today (Barc) 2018; 54 (11) 647-655
MissingFormLabel
- 77
Al-Samkari H,
Kuter DJ.
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag
and romiplostim in a patient with chronic immune thrombocytopenia. Br J Haematol 2018;
183 (02) 168
MissingFormLabel
- 78
Kuter DJ,
Macahilig C,
Grotzinger KM.
et al.
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia
(ITP) switched to eltrombopag or romiplostim. Int J Hematol 2015; 101 (03) 255-263
MissingFormLabel
- 79
GlaxoSmithKline.
Promacta (Eltrombopag) [Prescribing Information]. Research Triangle Park, NC: 2017
MissingFormLabel
- 80
Al-Samkari H,
Kuter DJ.
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic
immune thrombocytopenia. Br J Clin Pharmacol 2018; 84 (11) 2673-2677
MissingFormLabel
- 81
Amgen I.
Nplate (Romiplostim) [Prescribing Information]. Thousand Oaks, CA: Amgen; October
2017
MissingFormLabel
- 82
Kuter DJ,
Rummel M,
Boccia R.
et al.
Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J
Med 2010; 363 (20) 1889-1899
MissingFormLabel
- 83
Steurer M,
Quittet P,
Papadaki HA.
et al.
A large observational study of patients with primary immune thrombocytopenia receiving
romiplostim in European clinical practice. Eur J Haematol 2017; 98 (02) 112-120
MissingFormLabel
- 84
Jurczak W,
Chojnowski K,
Mayer J.
et al.
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist
for the treatment of chronic immune thrombocytopenia. Br J Haematol 2018; 183 (03)
479-490
MissingFormLabel
- 85
Psaila B,
Bussel JB,
Linden MD.
et al.
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no
evidence of platelet activation. Blood 2012; 119 (17) 4066-4072
MissingFormLabel
- 86
Al-Samkari H,
Van Cott EM,
Kuter DJ.
Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
Ann Hematol 2019; 98 (03) 581-588
MissingFormLabel
- 87
Bussel JB,
Kuter DJ,
Pullarkat V,
Lyons RM,
Guo M,
Nichol JL.
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients
with chronic ITP. Blood 2009; 113 (10) 2161-2171
MissingFormLabel
- 88
Cines DB,
Gernsheimer T,
Wasser J.
et al.
Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia
(ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol
2015; 102 (03) 259-270
MissingFormLabel
- 89
Kuter DJ,
Mufti GJ,
Bain BJ,
Hasserjian RP,
Davis W,
Rutstein M.
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients
treated with romiplostim. Blood 2009; 114 (18) 3748-3756
MissingFormLabel
- 90
Janssens A,
Rodeghiero F,
Anderson D.
et al.
Changes in bone marrow morphology in adults receiving romiplostim for the treatment
of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol 2016;
95 (07) 1077-1087
MissingFormLabel
- 91
Kantarjian HM,
Fenaux P,
Sekeres MA.
et al.
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic
patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo
in a randomised double-blind trial. Lancet Haematol 2018; 5 (03) e117-e126
MissingFormLabel
- 92
Ghanima W,
Khelif A,
Waage A.
et al;
RITP Study Group.
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial):
a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 385
(9978): 1653-1661
MissingFormLabel
- 93
Pasa S,
Altintas A,
Cil T,
Danis R,
Ayyildiz O.
The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic
thrombocythopenic purpura. J Thromb Thrombolysis 2009; 27 (03) 329-333
MissingFormLabel
- 94
Červinek L,
Černá O,
Čaniga M.
et al.
Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated
patients from everyday hematological practice. Int J Hematol 2012; 96 (05) 594-599
MissingFormLabel
- 95
Mahévas M,
Ebbo M,
Audia S.
et al.
Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the
standard regimen to treat adult immune thrombocytopenia. Am J Hematol 2013; 88 (10)
858-861
MissingFormLabel
- 96
Tran H,
Brighton T,
Grigg A.
et al.
A multi-centre, single-arm, open-label study evaluating the safety and efficacy of
fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic
purpura (R-ITP1000 study). Br J Haematol 2014; 167 (02) 243-251
MissingFormLabel
- 97
Khellaf M,
Charles-Nelson A,
Fain O.
et al.
Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a
prospective registry including 248 patients. Blood 2014; 124 (22) 3228-3236
MissingFormLabel
- 98
Zaja F,
Vianelli N,
Volpetti S.
et al.
Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol
2010; 85 (04) 329-334
MissingFormLabel
- 99
Zaja F,
Volpetti S,
Chiozzotto M.
et al.
Long-term follow-up analysis after rituximab salvage therapy in adult patients with
immune thrombocytopenia. Am J Hematol 2012; 87 (09) 886-889
MissingFormLabel
- 100
Vikse J,
Jonsdottir K,
Kvaløy JT,
Wildhagen K,
Omdal R.
Tolerability and safety of long-term rituximab treatment in systemic inflammatory
and autoimmune diseases. Rheumatol Int 2019; 39 (06) 1083-1090
MissingFormLabel
- 101
Markham A.
Fostamatinib: first global approval. Drugs 2018; 78 (09) 959-963
MissingFormLabel
- 102
Bussel J,
Arnold DM,
Grossbard E.
et al.
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia:
results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 2018;
93 (07) 921-930
MissingFormLabel
- 103
Bussel JB,
Arnold DM,
Boxer MA.
et al.
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the
phase 3 clinical trial program. Am J Hematol 2019; 94 (05) 546-553
MissingFormLabel
- 104
Tomiyama Y,
Miyakawa Y,
Okamoto S.
et al.
A lower starting dose of eltrombopag is efficacious in Japanese patients with previously
treated chronic immune thrombocytopenia. J Thromb Haemost 2012; 10 (05) 799-806
MissingFormLabel
- 105
Yang R,
Hou M,
Li J.
et al.
Effect of eltrombopag on platelet response and safety results in Chinese adults with
chronic ITP-primary result of a phase III study [abstract]. Blood 2014; 124 (21) 1464
MissingFormLabel
- 106
Shirasugi Y,
Ando K,
Miyazaki K.
et al.
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese
patients: a double-blind, randomized Phase III clinical trial. Int J Hematol 2011;
94 (01) 71-80
MissingFormLabel
- 107
Al-Samkari H,
Kuter DJ.
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther
Adv Hematol 2019. Doi: 10.1177/2040620719841735 [epub ahead of print]
MissingFormLabel
- 108
Quiquandon I,
Fenaux P,
Caulier MT,
Pagniez D,
Huart JJ,
Bauters F.
Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic
thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990; 74 (02) 223-228
MissingFormLabel
- 109
Verlin M,
Laros Jr RK,
Penner JA.
Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol
1976; 1 (01) 97-104
MissingFormLabel
- 110
Pizzuto J,
Ambriz R.
Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric
trial of the Cooperative Latin American group on hemostasis and thrombosis. Blood
1984; 64 (06) 1179-1183
MissingFormLabel
- 111
Choudhary DR,
Naithani R,
Mahapatra M,
Kumar R,
Mishra P,
Saxena R.
Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic
purpura. Haematologica 2008; 93 (10) e61-e62 , discussion e63
MissingFormLabel
- 112
Kappers-Klunne MC,
van't Veer MB.
Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic
purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001; 114 (01)
121-125
MissingFormLabel
- 113
Fenaux P,
Quiquandon I,
Huart JJ,
Caulier MT,
Bauters F.
The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura.
A report of 22 cases. Nouv Rev Fr Hematol 1990; 32 (02) 143-146
MissingFormLabel
- 114
Li HQ,
Zhang L,
Zhao H,
Ji LX,
Yang RC.
Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: a retrospective
single-centered analysis of 1791 cases. Chin Med J (Engl) 2005; 118 (01) 34-37
MissingFormLabel
- 115
Liu W,
Gu X,
Fu R.
et al.
The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort
from a single center in China. Clin Appl Thromb Hemost 2016; 22 (08) 727-733
MissingFormLabel
- 116
Maloisel F,
Andrès E,
Zimmer J.
et al.
Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term
results. Am J Med 2004; 116 (09) 590-594
MissingFormLabel
- 117
Damodar S,
Viswabandya A,
George B,
Mathews V,
Chandy M,
Srivastava A.
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a
report on 90 patients. Eur J Haematol 2005; 75 (04) 328-331
MissingFormLabel
- 118
Godeau B,
Durand JM,
Roudot-Thoraval F.
et al.
Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br
J Haematol 1997; 97 (02) 336-339
MissingFormLabel
- 119
Zaja F,
Marin L,
Chiozzotto M,
Puglisi S,
Volpetti S,
Fanin R.
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or
refractory to steroid and rituximab. Am J Hematol 2012; 87 (03) 321-323
MissingFormLabel
- 120
Hou M,
Peng J,
Shi Y.
et al.
Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic
purpura. Eur J Haematol 2003; 70 (06) 353-357
MissingFormLabel
- 121
Taylor A,
Neave L,
Solanki S.
et al.
Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol 2015;
171 (04) 625-630
MissingFormLabel
- 122
Zhang WG,
Ji L,
Cao XM.
et al.
Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura.
Acta Pharmacol Sin 2005; 26 (05) 598-602
MissingFormLabel
- 123
Ahn YS,
Harrington WJ,
Mylvaganam R,
Allen LM,
Pall LM.
Slow infusion of Vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura.
Ann Intern Med 1984; 100 (02) 192-196
MissingFormLabel
- 124
Facon T,
Caulier MT,
Wattel E,
Jouet JP,
Bauters F,
Fenaux P.
A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection
in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol 1994;
86 (03) 678-680
MissingFormLabel
- 125
Fenaux P,
Quiquandon I,
Caulier MT,
Simon M,
Walter MP,
Bauters F.
Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic
purpura: a report on 43 cases. Blut 1990; 60 (04) 238-241
MissingFormLabel
- 126
Park YH,
Yi HG,
Lee MH,
Kim CS,
Lim JH.
Clinical efficacy and tolerability of vincristine in splenectomized patients with
refractory or relapsed immune thrombocytopenia: a retrospective single-center study.
Int J Hematol 2016; 103 (02) 180-188
MissingFormLabel